Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
All content for From Lab to Launch by Qualio is the property of Qualio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
The proof is in the protein with Dr. Jonathan Usuka, CEO of Sapient
From Lab to Launch by Qualio
16 minutes
3 months ago
The proof is in the protein with Dr. Jonathan Usuka, CEO of Sapient
If you’ve been following From Lab to Launch for a while, you may remember a previous conversation with Sapient’s Chief Scientific Officer, Dr. Mo Jain, a couple years back. We’re thrilled to build on that conversation with Dr. Jonathan Usuka, the CEO of Sapient. Sapient is one of the largest capacity biomarker discovery labs in the world, and their mission is to accelerate drug development and improve patient outcomes through biomarker-guided therapeutics. By combining high-resolution b...
From Lab to Launch by Qualio
Nora Khaldi is a mathematician with a Ph.D. in Molecular Evolution and Bioinformatics, and her years of research have focused primarily on protein evolution and comparative genomics. Throughout her career, Nora’s ambition has been to disrupt the status quo in areas that have been void of technology by introducing new ways of thinking, big data, and new algorithms. In 2014, she founded Nuritas, a Dublin-based biotech company that counts U2’s Bono and The Edge among its investors. Nuritas has c...
